The estimated Net Worth of Martin Dekker is at least $413 Tisíc dollars as of 9 December 2022. Mr. Dekker owns over 25,500 units of Bellerophon Therapeutics Inc stock worth over $1,020 and over the last 9 years he sold BLPH stock worth over $0. In addition, he makes $412,083 as Vice President - Engineering and Manufacturing at Bellerophon Therapeutics Inc.
Martin has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 25,500 units of BLPH stock worth $1,020 on 9 December 2022.
The largest trade he's ever made was exercising 25,500 units of Bellerophon Therapeutics Inc stock on 9 December 2022 worth over $1,020. On average, Martin trades about 1,500 units every 0 days since 2016. As of 9 December 2022 he still owns at least 25,500 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Mr. Dekker stock trades at the bottom of the page.
Martin Dekker serves as Vice President - Engineering and Manufacturing of the Company. Mr. Dekker held several positions at Spacelabs Healthcare, a company that develops and manufactures medical devices, from November 1998 to January 2015, most recently as Director of Global Operations Engineering. During his time at Spacelabs Healthcare, Mr. Dekker led and co-designed new products, developed and launched transformative manufacturing technologies and championed cross-functional quality/engineering projects. He is a member of the Institute of Electrical and Electronic Engineers. Mr. Dekker received a B.S. in electronics from Noordelijke Hogeschool Leeuwarden, the Netherlands.
As the Vice President - Engineering and Manufacturing of Bellerophon Therapeutics Inc, the total compensation of Martin Dekker at Bellerophon Therapeutics Inc is $412,083. There are 4 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of $1,400,000.
Martin Dekker is 47, he's been the Vice President - Engineering and Manufacturing of Bellerophon Therapeutics Inc since 2015. There are 10 older and 7 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
Martin's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein a Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: